nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—HTR1D—meninx—melanoma	0.0349	0.287	CbGeAlD
Pergolide—CYP3A4—Temozolomide—melanoma	0.0333	0.385	CbGbCtD
Pergolide—DRD5—eyelid—melanoma	0.0316	0.26	CbGeAlD
Pergolide—CYP2D6—Vemurafenib—melanoma	0.0287	0.332	CbGbCtD
Pergolide—CYP3A4—Vemurafenib—melanoma	0.0183	0.211	CbGbCtD
Pergolide—CYP3A4—Docetaxel—melanoma	0.00626	0.0724	CbGbCtD
Pergolide—HTR2A—hindlimb—melanoma	0.00412	0.0339	CbGeAlD
Pergolide—HTR1B—blood vessel—melanoma	0.00409	0.0337	CbGeAlD
Pergolide—HTR1D—blood vessel—melanoma	0.00396	0.0326	CbGeAlD
Pergolide—HTR2A—appendage—melanoma	0.00353	0.0291	CbGeAlD
Pergolide—HTR2A—endothelium—melanoma	0.00213	0.0176	CbGeAlD
Pergolide—DRD3—head—melanoma	0.00213	0.0175	CbGeAlD
Pergolide—HTR1D—eye—melanoma	0.00211	0.0173	CbGeAlD
Pergolide—DRD5—head—melanoma	0.002	0.0164	CbGeAlD
Pergolide—HTR2A—blood vessel—melanoma	0.00197	0.0162	CbGeAlD
Pergolide—HTR2B—skin of body—melanoma	0.00171	0.014	CbGeAlD
Pergolide—ADRA1B—head—melanoma	0.00164	0.0135	CbGeAlD
Pergolide—ADRA1D—head—melanoma	0.0016	0.0132	CbGeAlD
Pergolide—DRD2—eye—melanoma	0.00159	0.0131	CbGeAlD
Pergolide—DRD2—retina—melanoma	0.00157	0.0129	CbGeAlD
Pergolide—DRD1—head—melanoma	0.00152	0.0126	CbGeAlD
Pergolide—HTR2A—neck—melanoma	0.00141	0.0116	CbGeAlD
Pergolide—HTR1B—head—melanoma	0.00124	0.0102	CbGeAlD
Pergolide—ADRA2C—mammalian vulva—melanoma	0.00122	0.0101	CbGeAlD
Pergolide—HTR1D—head—melanoma	0.0012	0.00985	CbGeAlD
Pergolide—HTR2C—head—melanoma	0.00118	0.00975	CbGeAlD
Pergolide—HTR2B—head—melanoma	0.00111	0.00916	CbGeAlD
Pergolide—HTR2A—eye—melanoma	0.00105	0.00862	CbGeAlD
Pergolide—HTR2A—retina—melanoma	0.00104	0.00854	CbGeAlD
Pergolide—HTR1A—head—melanoma	0.000997	0.00821	CbGeAlD
Pergolide—ADRA2A—mammalian vulva—melanoma	0.000977	0.00804	CbGeAlD
Pergolide—ADRA1A—head—melanoma	0.000919	0.00757	CbGeAlD
Pergolide—DRD2—head—melanoma	0.000901	0.00742	CbGeAlD
Pergolide—KCNH2—head—melanoma	0.000888	0.00731	CbGeAlD
Pergolide—ADRA2C—head—melanoma	0.000876	0.00721	CbGeAlD
Pergolide—Weight increased—Temozolomide—melanoma	0.00085	0.00196	CcSEcCtD
Pergolide—Renal failure—Carmustine—melanoma	0.000848	0.00195	CcSEcCtD
Pergolide—Weight decreased—Temozolomide—melanoma	0.000845	0.00195	CcSEcCtD
Pergolide—Neuropathy peripheral—Carmustine—melanoma	0.000845	0.00195	CcSEcCtD
Pergolide—Hyperglycaemia—Temozolomide—melanoma	0.000843	0.00194	CcSEcCtD
Pergolide—Urinary tract infection—Carmustine—melanoma	0.000838	0.00193	CcSEcCtD
Pergolide—Pneumonia—Temozolomide—melanoma	0.000838	0.00193	CcSEcCtD
Pergolide—Depression—Temozolomide—melanoma	0.000831	0.00191	CcSEcCtD
Pergolide—Thrombophlebitis—Docetaxel—melanoma	0.000831	0.00191	CcSEcCtD
Pergolide—Hepatitis—Dactinomycin—melanoma	0.000827	0.00191	CcSEcCtD
Pergolide—Body temperature increased—Vemurafenib—melanoma	0.000822	0.00189	CcSEcCtD
Pergolide—Pharyngitis—Dactinomycin—melanoma	0.000821	0.00189	CcSEcCtD
Pergolide—Neuropathy peripheral—Temozolomide—melanoma	0.000817	0.00188	CcSEcCtD
Pergolide—Urinary tract infection—Temozolomide—melanoma	0.00081	0.00187	CcSEcCtD
Pergolide—Deafness—Docetaxel—melanoma	0.000804	0.00185	CcSEcCtD
Pergolide—Chills—Bleomycin—melanoma	0.000796	0.00183	CcSEcCtD
Pergolide—Cardiac failure congestive—Docetaxel—melanoma	0.000793	0.00183	CcSEcCtD
Pergolide—Alopecia—Bleomycin—melanoma	0.000784	0.00181	CcSEcCtD
Pergolide—Sinusitis—Temozolomide—melanoma	0.000782	0.0018	CcSEcCtD
Pergolide—HTR2B—lymph node—melanoma	0.000779	0.00641	CbGeAlD
Pergolide—Hallucination—Carmustine—melanoma	0.00077	0.00177	CcSEcCtD
Pergolide—Oedema peripheral—Carmustine—melanoma	0.000762	0.00176	CcSEcCtD
Pergolide—Atrial fibrillation—Docetaxel—melanoma	0.000759	0.00175	CcSEcCtD
Pergolide—Dermatitis bullous—Docetaxel—melanoma	0.000752	0.00173	CcSEcCtD
Pergolide—Hepatitis—Temozolomide—melanoma	0.000748	0.00172	CcSEcCtD
Pergolide—Asthenia—Vemurafenib—melanoma	0.000746	0.00172	CcSEcCtD
Pergolide—Visual impairment—Carmustine—melanoma	0.000746	0.00172	CcSEcCtD
Pergolide—Hallucination—Temozolomide—melanoma	0.000744	0.00171	CcSEcCtD
Pergolide—Pharyngitis—Temozolomide—melanoma	0.000742	0.00171	CcSEcCtD
Pergolide—Chills—Dactinomycin—melanoma	0.000742	0.00171	CcSEcCtD
Pergolide—Oedema peripheral—Temozolomide—melanoma	0.000737	0.0017	CcSEcCtD
Pergolide—Pruritus—Vemurafenib—melanoma	0.000736	0.00169	CcSEcCtD
Pergolide—Alopecia—Dactinomycin—melanoma	0.000731	0.00168	CcSEcCtD
Pergolide—Eye disorder—Carmustine—melanoma	0.000723	0.00167	CcSEcCtD
Pergolide—Visual impairment—Temozolomide—melanoma	0.000721	0.00166	CcSEcCtD
Pergolide—Ill-defined disorder—Bleomycin—melanoma	0.000716	0.00165	CcSEcCtD
Pergolide—Anaemia—Bleomycin—melanoma	0.000713	0.00164	CcSEcCtD
Pergolide—Diarrhoea—Vemurafenib—melanoma	0.000711	0.00164	CcSEcCtD
Pergolide—Migraine—Docetaxel—melanoma	0.000708	0.00163	CcSEcCtD
Pergolide—Eye disorder—Temozolomide—melanoma	0.000699	0.00161	CcSEcCtD
Pergolide—ADRA2A—head—melanoma	0.000699	0.00575	CbGeAlD
Pergolide—Tinnitus—Temozolomide—melanoma	0.000697	0.00161	CcSEcCtD
Pergolide—Malaise—Bleomycin—melanoma	0.000696	0.0016	CcSEcCtD
Pergolide—Arrhythmia—Carmustine—melanoma	0.000691	0.00159	CcSEcCtD
Pergolide—Leukopenia—Bleomycin—melanoma	0.000691	0.00159	CcSEcCtD
Pergolide—Dizziness—Vemurafenib—melanoma	0.000688	0.00158	CcSEcCtD
Pergolide—Alopecia—Carmustine—melanoma	0.000684	0.00158	CcSEcCtD
Pergolide—Ataxia—Docetaxel—melanoma	0.000676	0.00156	CcSEcCtD
Pergolide—Cough—Bleomycin—melanoma	0.000674	0.00155	CcSEcCtD
Pergolide—Chills—Temozolomide—melanoma	0.000671	0.00155	CcSEcCtD
Pergolide—Dehydration—Docetaxel—melanoma	0.000669	0.00154	CcSEcCtD
Pergolide—Ill-defined disorder—Dactinomycin—melanoma	0.000668	0.00154	CcSEcCtD
Pergolide—Anaemia—Dactinomycin—melanoma	0.000665	0.00153	CcSEcCtD
Pergolide—Liver function test abnormal—Docetaxel—melanoma	0.000664	0.00153	CcSEcCtD
Pergolide—Vomiting—Vemurafenib—melanoma	0.000661	0.00152	CcSEcCtD
Pergolide—Alopecia—Temozolomide—melanoma	0.000661	0.00152	CcSEcCtD
Pergolide—Dry skin—Docetaxel—melanoma	0.000659	0.00152	CcSEcCtD
Pergolide—Chest pain—Bleomycin—melanoma	0.000657	0.00151	CcSEcCtD
Pergolide—Myalgia—Bleomycin—melanoma	0.000657	0.00151	CcSEcCtD
Pergolide—Orthostatic hypotension—Docetaxel—melanoma	0.000657	0.00151	CcSEcCtD
Pergolide—Rash—Vemurafenib—melanoma	0.000656	0.00151	CcSEcCtD
Pergolide—Dermatitis—Vemurafenib—melanoma	0.000655	0.00151	CcSEcCtD
Pergolide—Back pain—Carmustine—melanoma	0.000652	0.0015	CcSEcCtD
Pergolide—Headache—Vemurafenib—melanoma	0.000651	0.0015	CcSEcCtD
Pergolide—Discomfort—Bleomycin—melanoma	0.000649	0.0015	CcSEcCtD
Pergolide—Malaise—Dactinomycin—melanoma	0.000649	0.0015	CcSEcCtD
Pergolide—Leukopenia—Dactinomycin—melanoma	0.000644	0.00148	CcSEcCtD
Pergolide—Dysgeusia—Temozolomide—melanoma	0.000638	0.00147	CcSEcCtD
Pergolide—Confusional state—Bleomycin—melanoma	0.000635	0.00146	CcSEcCtD
Pergolide—Tremor—Carmustine—melanoma	0.000631	0.00145	CcSEcCtD
Pergolide—Oedema—Bleomycin—melanoma	0.00063	0.00145	CcSEcCtD
Pergolide—Back pain—Temozolomide—melanoma	0.00063	0.00145	CcSEcCtD
Pergolide—Infection—Bleomycin—melanoma	0.000626	0.00144	CcSEcCtD
Pergolide—Anaemia—Carmustine—melanoma	0.000623	0.00143	CcSEcCtD
Pergolide—KCNH2—lymph node—melanoma	0.000622	0.00512	CbGeAlD
Pergolide—Dysphagia—Docetaxel—melanoma	0.000621	0.00143	CcSEcCtD
Pergolide—Agitation—Carmustine—melanoma	0.000619	0.00143	CcSEcCtD
Pergolide—Nausea—Vemurafenib—melanoma	0.000618	0.00142	CcSEcCtD
Pergolide—Thrombocytopenia—Bleomycin—melanoma	0.000617	0.00142	CcSEcCtD
Pergolide—ADRA2C—lymph node—melanoma	0.000613	0.00505	CbGeAlD
Pergolide—Myalgia—Dactinomycin—melanoma	0.000613	0.00141	CcSEcCtD
Pergolide—Tremor—Temozolomide—melanoma	0.00061	0.00141	CcSEcCtD
Pergolide—Discomfort—Dactinomycin—melanoma	0.000606	0.0014	CcSEcCtD
Pergolide—Angina pectoris—Docetaxel—melanoma	0.000605	0.00139	CcSEcCtD
Pergolide—Ill-defined disorder—Temozolomide—melanoma	0.000604	0.00139	CcSEcCtD
Pergolide—Leukopenia—Carmustine—melanoma	0.000603	0.00139	CcSEcCtD
Pergolide—Anaemia—Temozolomide—melanoma	0.000602	0.00139	CcSEcCtD
Pergolide—Anorexia—Bleomycin—melanoma	0.0006	0.00138	CcSEcCtD
Pergolide—Agitation—Temozolomide—melanoma	0.000598	0.00138	CcSEcCtD
Pergolide—HTR2A—head—melanoma	0.000594	0.00489	CbGeAlD
Pergolide—Hypotension—Bleomycin—melanoma	0.000589	0.00136	CcSEcCtD
Pergolide—Oedema—Dactinomycin—melanoma	0.000588	0.00135	CcSEcCtD
Pergolide—Malaise—Temozolomide—melanoma	0.000587	0.00135	CcSEcCtD
Pergolide—Vertigo—Temozolomide—melanoma	0.000585	0.00135	CcSEcCtD
Pergolide—Convulsion—Carmustine—melanoma	0.000584	0.00135	CcSEcCtD
Pergolide—Infection—Dactinomycin—melanoma	0.000584	0.00134	CcSEcCtD
Pergolide—Leukopenia—Temozolomide—melanoma	0.000583	0.00134	CcSEcCtD
Pergolide—Hypertension—Carmustine—melanoma	0.000582	0.00134	CcSEcCtD
Pergolide—Palpitations—Temozolomide—melanoma	0.000575	0.00133	CcSEcCtD
Pergolide—Thrombocytopenia—Dactinomycin—melanoma	0.000575	0.00133	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000574	0.00132	CcSEcCtD
Pergolide—Chest pain—Carmustine—melanoma	0.000574	0.00132	CcSEcCtD
Pergolide—Myalgia—Carmustine—melanoma	0.000574	0.00132	CcSEcCtD
Pergolide—Anxiety—Carmustine—melanoma	0.000572	0.00132	CcSEcCtD
Pergolide—Cough—Temozolomide—melanoma	0.000568	0.00131	CcSEcCtD
Pergolide—Paraesthesia—Bleomycin—melanoma	0.000566	0.0013	CcSEcCtD
Pergolide—Weight increased—Docetaxel—melanoma	0.000566	0.0013	CcSEcCtD
Pergolide—Convulsion—Temozolomide—melanoma	0.000564	0.0013	CcSEcCtD
Pergolide—Weight decreased—Docetaxel—melanoma	0.000562	0.0013	CcSEcCtD
Pergolide—Hypertension—Temozolomide—melanoma	0.000562	0.0013	CcSEcCtD
Pergolide—Dyspnoea—Bleomycin—melanoma	0.000562	0.00129	CcSEcCtD
Pergolide—Anorexia—Dactinomycin—melanoma	0.00056	0.00129	CcSEcCtD
Pergolide—Pneumonia—Docetaxel—melanoma	0.000557	0.00128	CcSEcCtD
Pergolide—Confusional state—Carmustine—melanoma	0.000554	0.00128	CcSEcCtD
Pergolide—Myalgia—Temozolomide—melanoma	0.000554	0.00128	CcSEcCtD
Pergolide—Arthralgia—Temozolomide—melanoma	0.000554	0.00128	CcSEcCtD
Pergolide—Anxiety—Temozolomide—melanoma	0.000552	0.00127	CcSEcCtD
Pergolide—Oedema—Carmustine—melanoma	0.00055	0.00127	CcSEcCtD
Pergolide—Discomfort—Temozolomide—melanoma	0.000548	0.00126	CcSEcCtD
Pergolide—Decreased appetite—Bleomycin—melanoma	0.000548	0.00126	CcSEcCtD
Pergolide—Infection—Carmustine—melanoma	0.000546	0.00126	CcSEcCtD
Pergolide—Acute coronary syndrome—Docetaxel—melanoma	0.000546	0.00126	CcSEcCtD
Pergolide—Renal failure—Docetaxel—melanoma	0.000545	0.00125	CcSEcCtD
Pergolide—Neuropathy peripheral—Docetaxel—melanoma	0.000543	0.00125	CcSEcCtD
Pergolide—Myocardial infarction—Docetaxel—melanoma	0.000543	0.00125	CcSEcCtD
Pergolide—Dry mouth—Temozolomide—melanoma	0.000542	0.00125	CcSEcCtD
Pergolide—CYP2D6—head—melanoma	0.000541	0.00446	CbGeAlD
Pergolide—Jaundice—Docetaxel—melanoma	0.00054	0.00124	CcSEcCtD
Pergolide—Pain—Bleomycin—melanoma	0.000539	0.00124	CcSEcCtD
Pergolide—Conjunctivitis—Docetaxel—melanoma	0.000539	0.00124	CcSEcCtD
Pergolide—Thrombocytopenia—Carmustine—melanoma	0.000538	0.00124	CcSEcCtD
Pergolide—Tachycardia—Carmustine—melanoma	0.000537	0.00124	CcSEcCtD
Pergolide—Confusional state—Temozolomide—melanoma	0.000536	0.00123	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000535	0.00123	CcSEcCtD
Pergolide—Oedema—Temozolomide—melanoma	0.000531	0.00122	CcSEcCtD
Pergolide—Infection—Temozolomide—melanoma	0.000528	0.00122	CcSEcCtD
Pergolide—Anorexia—Carmustine—melanoma	0.000524	0.00121	CcSEcCtD
Pergolide—Epistaxis—Docetaxel—melanoma	0.000523	0.0012	CcSEcCtD
Pergolide—Thrombocytopenia—Temozolomide—melanoma	0.00052	0.0012	CcSEcCtD
Pergolide—Feeling abnormal—Bleomycin—melanoma	0.000519	0.0012	CcSEcCtD
Pergolide—Hypotension—Carmustine—melanoma	0.000514	0.00118	CcSEcCtD
Pergolide—Hyperhidrosis—Temozolomide—melanoma	0.000514	0.00118	CcSEcCtD
Pergolide—Decreased appetite—Dactinomycin—melanoma	0.000511	0.00118	CcSEcCtD
Pergolide—Anorexia—Temozolomide—melanoma	0.000507	0.00117	CcSEcCtD
Pergolide—Pain—Dactinomycin—melanoma	0.000502	0.00116	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Carmustine—melanoma	0.000501	0.00115	CcSEcCtD
Pergolide—Rhinitis—Docetaxel—melanoma	0.000499	0.00115	CcSEcCtD
Pergolide—Body temperature increased—Bleomycin—melanoma	0.000498	0.00115	CcSEcCtD
Pergolide—Hepatitis—Docetaxel—melanoma	0.000497	0.00115	CcSEcCtD
Pergolide—Insomnia—Carmustine—melanoma	0.000497	0.00115	CcSEcCtD
Pergolide—Paraesthesia—Carmustine—melanoma	0.000494	0.00114	CcSEcCtD
Pergolide—Pharyngitis—Docetaxel—melanoma	0.000494	0.00114	CcSEcCtD
Pergolide—Dyspnoea—Carmustine—melanoma	0.00049	0.00113	CcSEcCtD
Pergolide—Oedema peripheral—Docetaxel—melanoma	0.00049	0.00113	CcSEcCtD
Pergolide—ADRA2A—lymph node—melanoma	0.000489	0.00403	CbGeAlD
Pergolide—Somnolence—Carmustine—melanoma	0.000489	0.00113	CcSEcCtD
Pergolide—Feeling abnormal—Dactinomycin—melanoma	0.000484	0.00112	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000484	0.00112	CcSEcCtD
Pergolide—Insomnia—Temozolomide—melanoma	0.000481	0.00111	CcSEcCtD
Pergolide—Gastrointestinal pain—Dactinomycin—melanoma	0.00048	0.00111	CcSEcCtD
Pergolide—Visual impairment—Docetaxel—melanoma	0.000479	0.0011	CcSEcCtD
Pergolide—Decreased appetite—Carmustine—melanoma	0.000478	0.0011	CcSEcCtD
Pergolide—Paraesthesia—Temozolomide—melanoma	0.000477	0.0011	CcSEcCtD
Pergolide—Dyspnoea—Temozolomide—melanoma	0.000474	0.00109	CcSEcCtD
Pergolide—Somnolence—Temozolomide—melanoma	0.000472	0.00109	CcSEcCtD
Pergolide—Pain—Carmustine—melanoma	0.00047	0.00108	CcSEcCtD
Pergolide—Constipation—Carmustine—melanoma	0.00047	0.00108	CcSEcCtD
Pergolide—Dyspepsia—Temozolomide—melanoma	0.000468	0.00108	CcSEcCtD
Pergolide—Eye disorder—Docetaxel—melanoma	0.000465	0.00107	CcSEcCtD
Pergolide—Abdominal pain—Dactinomycin—melanoma	0.000464	0.00107	CcSEcCtD
Pergolide—Body temperature increased—Dactinomycin—melanoma	0.000464	0.00107	CcSEcCtD
Pergolide—Decreased appetite—Temozolomide—melanoma	0.000462	0.00106	CcSEcCtD
Pergolide—Pain—Temozolomide—melanoma	0.000454	0.00105	CcSEcCtD
Pergolide—Constipation—Temozolomide—melanoma	0.000454	0.00105	CcSEcCtD
Pergolide—Feeling abnormal—Carmustine—melanoma	0.000453	0.00104	CcSEcCtD
Pergolide—Asthenia—Bleomycin—melanoma	0.000452	0.00104	CcSEcCtD
Pergolide—Gastrointestinal pain—Carmustine—melanoma	0.00045	0.00104	CcSEcCtD
Pergolide—Chills—Docetaxel—melanoma	0.000446	0.00103	CcSEcCtD
Pergolide—Pruritus—Bleomycin—melanoma	0.000446	0.00103	CcSEcCtD
Pergolide—Arrhythmia—Docetaxel—melanoma	0.000444	0.00102	CcSEcCtD
Pergolide—Alopecia—Docetaxel—melanoma	0.00044	0.00101	CcSEcCtD
Pergolide—Feeling abnormal—Temozolomide—melanoma	0.000438	0.00101	CcSEcCtD
Pergolide—Abdominal pain—Carmustine—melanoma	0.000435	0.001	CcSEcCtD
Pergolide—Body temperature increased—Carmustine—melanoma	0.000435	0.001	CcSEcCtD
Pergolide—Gastrointestinal pain—Temozolomide—melanoma	0.000435	0.001	CcSEcCtD
Pergolide—Dysgeusia—Docetaxel—melanoma	0.000424	0.000977	CcSEcCtD
Pergolide—Asthenia—Dactinomycin—melanoma	0.000422	0.000971	CcSEcCtD
Pergolide—Abdominal pain—Temozolomide—melanoma	0.00042	0.000968	CcSEcCtD
Pergolide—Body temperature increased—Temozolomide—melanoma	0.00042	0.000968	CcSEcCtD
Pergolide—Back pain—Docetaxel—melanoma	0.000419	0.000965	CcSEcCtD
Pergolide—Diarrhoea—Dactinomycin—melanoma	0.000402	0.000926	CcSEcCtD
Pergolide—Vomiting—Bleomycin—melanoma	0.000401	0.000923	CcSEcCtD
Pergolide—Anaemia—Docetaxel—melanoma	0.0004	0.000922	CcSEcCtD
Pergolide—Rash—Bleomycin—melanoma	0.000397	0.000915	CcSEcCtD
Pergolide—Dermatitis—Bleomycin—melanoma	0.000397	0.000914	CcSEcCtD
Pergolide—Asthenia—Carmustine—melanoma	0.000395	0.000909	CcSEcCtD
Pergolide—Syncope—Docetaxel—melanoma	0.000388	0.000895	CcSEcCtD
Pergolide—Leukopenia—Docetaxel—melanoma	0.000388	0.000893	CcSEcCtD
Pergolide—Palpitations—Docetaxel—melanoma	0.000383	0.000882	CcSEcCtD
Pergolide—Asthenia—Temozolomide—melanoma	0.000381	0.000878	CcSEcCtD
Pergolide—Loss of consciousness—Docetaxel—melanoma	0.000381	0.000877	CcSEcCtD
Pergolide—Cough—Docetaxel—melanoma	0.000378	0.000871	CcSEcCtD
Pergolide—Diarrhoea—Carmustine—melanoma	0.000376	0.000867	CcSEcCtD
Pergolide—Pruritus—Temozolomide—melanoma	0.000376	0.000866	CcSEcCtD
Pergolide—Convulsion—Docetaxel—melanoma	0.000375	0.000864	CcSEcCtD
Pergolide—Nausea—Bleomycin—melanoma	0.000374	0.000862	CcSEcCtD
Pergolide—Hypertension—Docetaxel—melanoma	0.000374	0.000861	CcSEcCtD
Pergolide—Vomiting—Dactinomycin—melanoma	0.000374	0.000861	CcSEcCtD
Pergolide—Rash—Dactinomycin—melanoma	0.00037	0.000854	CcSEcCtD
Pergolide—Myalgia—Docetaxel—melanoma	0.000369	0.000849	CcSEcCtD
Pergolide—Arthralgia—Docetaxel—melanoma	0.000369	0.000849	CcSEcCtD
Pergolide—Chest pain—Docetaxel—melanoma	0.000369	0.000849	CcSEcCtD
Pergolide—Dizziness—Carmustine—melanoma	0.000364	0.000838	CcSEcCtD
Pergolide—Diarrhoea—Temozolomide—melanoma	0.000364	0.000838	CcSEcCtD
Pergolide—Dry mouth—Docetaxel—melanoma	0.000361	0.000831	CcSEcCtD
Pergolide—Confusional state—Docetaxel—melanoma	0.000356	0.000821	CcSEcCtD
Pergolide—Oedema—Docetaxel—melanoma	0.000353	0.000814	CcSEcCtD
Pergolide—Dizziness—Temozolomide—melanoma	0.000351	0.00081	CcSEcCtD
Pergolide—Infection—Docetaxel—melanoma	0.000351	0.000809	CcSEcCtD
Pergolide—Vomiting—Carmustine—melanoma	0.00035	0.000806	CcSEcCtD
Pergolide—Nausea—Dactinomycin—melanoma	0.000349	0.000804	CcSEcCtD
Pergolide—Shock—Docetaxel—melanoma	0.000348	0.000801	CcSEcCtD
Pergolide—Rash—Carmustine—melanoma	0.000347	0.000799	CcSEcCtD
Pergolide—Dermatitis—Carmustine—melanoma	0.000346	0.000798	CcSEcCtD
Pergolide—Thrombocytopenia—Docetaxel—melanoma	0.000346	0.000797	CcSEcCtD
Pergolide—Tachycardia—Docetaxel—melanoma	0.000345	0.000795	CcSEcCtD
Pergolide—Headache—Carmustine—melanoma	0.000344	0.000794	CcSEcCtD
Pergolide—Vomiting—Temozolomide—melanoma	0.000338	0.000778	CcSEcCtD
Pergolide—Anorexia—Docetaxel—melanoma	0.000337	0.000776	CcSEcCtD
Pergolide—Rash—Temozolomide—melanoma	0.000335	0.000772	CcSEcCtD
Pergolide—Dermatitis—Temozolomide—melanoma	0.000335	0.000771	CcSEcCtD
Pergolide—Headache—Temozolomide—melanoma	0.000333	0.000767	CcSEcCtD
Pergolide—Hypotension—Docetaxel—melanoma	0.00033	0.000761	CcSEcCtD
Pergolide—Nausea—Carmustine—melanoma	0.000327	0.000753	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Docetaxel—melanoma	0.000322	0.000742	CcSEcCtD
Pergolide—Insomnia—Docetaxel—melanoma	0.00032	0.000736	CcSEcCtD
Pergolide—Paraesthesia—Docetaxel—melanoma	0.000317	0.000731	CcSEcCtD
Pergolide—Nausea—Temozolomide—melanoma	0.000316	0.000727	CcSEcCtD
Pergolide—Dyspnoea—Docetaxel—melanoma	0.000315	0.000726	CcSEcCtD
Pergolide—Somnolence—Docetaxel—melanoma	0.000314	0.000724	CcSEcCtD
Pergolide—Dyspepsia—Docetaxel—melanoma	0.000311	0.000717	CcSEcCtD
Pergolide—Decreased appetite—Docetaxel—melanoma	0.000307	0.000708	CcSEcCtD
Pergolide—Pain—Docetaxel—melanoma	0.000302	0.000696	CcSEcCtD
Pergolide—Constipation—Docetaxel—melanoma	0.000302	0.000696	CcSEcCtD
Pergolide—Feeling abnormal—Docetaxel—melanoma	0.000291	0.000671	CcSEcCtD
Pergolide—Gastrointestinal pain—Docetaxel—melanoma	0.000289	0.000666	CcSEcCtD
Pergolide—Abdominal pain—Docetaxel—melanoma	0.000279	0.000644	CcSEcCtD
Pergolide—Body temperature increased—Docetaxel—melanoma	0.000279	0.000644	CcSEcCtD
Pergolide—Asthenia—Docetaxel—melanoma	0.000254	0.000584	CcSEcCtD
Pergolide—Pruritus—Docetaxel—melanoma	0.00025	0.000576	CcSEcCtD
Pergolide—Diarrhoea—Docetaxel—melanoma	0.000242	0.000557	CcSEcCtD
Pergolide—Dizziness—Docetaxel—melanoma	0.000234	0.000538	CcSEcCtD
Pergolide—Vomiting—Docetaxel—melanoma	0.000225	0.000518	CcSEcCtD
Pergolide—Rash—Docetaxel—melanoma	0.000223	0.000513	CcSEcCtD
Pergolide—Dermatitis—Docetaxel—melanoma	0.000223	0.000513	CcSEcCtD
Pergolide—Headache—Docetaxel—melanoma	0.000221	0.00051	CcSEcCtD
Pergolide—Nausea—Docetaxel—melanoma	0.00021	0.000484	CcSEcCtD
Pergolide—DRD2—Signaling Pathways—CDKN1B—melanoma	8.51e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MYC—melanoma	8.51e-06	2.38e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MYC—melanoma	8.51e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTEN—melanoma	8.5e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NFKB1—melanoma	8.46e-06	2.36e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—melanoma	8.45e-06	2.36e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—melanoma	8.44e-06	2.36e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—MAPK1—melanoma	8.44e-06	2.36e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—EGFR—melanoma	8.44e-06	2.36e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—melanoma	8.43e-06	2.35e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—melanoma	8.42e-06	2.35e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL8—melanoma	8.4e-06	2.35e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—melanoma	8.39e-06	2.34e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	8.38e-06	2.34e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1B—melanoma	8.38e-06	2.34e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—melanoma	8.35e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MDM2—melanoma	8.35e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—melanoma	8.34e-06	2.33e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—melanoma	8.34e-06	2.33e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—melanoma	8.33e-06	2.33e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—MAPK1—melanoma	8.33e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—MAPK1—melanoma	8.33e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—melanoma	8.33e-06	2.33e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—melanoma	8.33e-06	2.33e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—melanoma	8.29e-06	2.32e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—melanoma	8.29e-06	2.32e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—melanoma	8.29e-06	2.31e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—melanoma	8.27e-06	2.31e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—melanoma	8.27e-06	2.31e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—melanoma	8.26e-06	2.31e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—melanoma	8.25e-06	2.31e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—ERBB2—melanoma	8.23e-06	2.3e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—melanoma	8.21e-06	2.29e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1B—melanoma	8.2e-06	2.29e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—melanoma	8.2e-06	2.29e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—melanoma	8.17e-06	2.28e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—melanoma	8.16e-06	2.28e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—melanoma	8.14e-06	2.27e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—melanoma	8.12e-06	2.27e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—melanoma	8.12e-06	2.27e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—melanoma	8.11e-06	2.27e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—melanoma	8.06e-06	2.25e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CTNNB1—melanoma	8.04e-06	2.25e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—melanoma	8.04e-06	2.25e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—melanoma	8.03e-06	2.24e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—melanoma	8.02e-06	2.24e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—melanoma	8e-06	2.23e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—melanoma	7.99e-06	2.23e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—melanoma	7.99e-06	2.23e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—melanoma	7.98e-06	2.23e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—melanoma	7.97e-06	2.23e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PPARG—melanoma	7.97e-06	2.23e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—melanoma	7.96e-06	2.23e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—melanoma	7.94e-06	2.22e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—melanoma	7.92e-06	2.21e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CTNNB1—melanoma	7.91e-06	2.21e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK3—melanoma	7.9e-06	2.21e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—melanoma	7.88e-06	2.2e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—melanoma	7.87e-06	2.2e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—melanoma	7.87e-06	2.2e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—melanoma	7.87e-06	2.2e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—melanoma	7.86e-06	2.19e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—melanoma	7.84e-06	2.19e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—melanoma	7.82e-06	2.19e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—melanoma	7.81e-06	2.18e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL8—melanoma	7.8e-06	2.18e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—melanoma	7.8e-06	2.18e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NFKB1—melanoma	7.8e-06	2.18e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—melanoma	7.77e-06	2.17e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—melanoma	7.76e-06	2.17e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—melanoma	7.75e-06	2.17e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CTNNB1—melanoma	7.75e-06	2.16e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—melanoma	7.73e-06	2.16e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—melanoma	7.73e-06	2.16e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—melanoma	7.71e-06	2.15e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—melanoma	7.71e-06	2.15e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—melanoma	7.69e-06	2.15e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—melanoma	7.68e-06	2.15e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NFKB1—melanoma	7.68e-06	2.14e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—melanoma	7.65e-06	2.14e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—melanoma	7.65e-06	2.14e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK3—melanoma	7.63e-06	2.13e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1B—melanoma	7.62e-06	2.13e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—melanoma	7.6e-06	2.12e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—melanoma	7.6e-06	2.12e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK3—melanoma	7.59e-06	2.12e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—melanoma	7.59e-06	2.12e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—melanoma	7.57e-06	2.11e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—melanoma	7.55e-06	2.11e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—melanoma	7.54e-06	2.11e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—melanoma	7.53e-06	2.1e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—melanoma	7.52e-06	2.1e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK1—melanoma	7.52e-06	2.1e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—melanoma	7.52e-06	2.1e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NFKB1—melanoma	7.52e-06	2.1e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—melanoma	7.51e-06	2.1e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ABCB1—melanoma	7.49e-06	2.09e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—melanoma	7.48e-06	2.09e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—melanoma	7.47e-06	2.09e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—melanoma	7.46e-06	2.08e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—melanoma	7.42e-06	2.07e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—melanoma	7.42e-06	2.07e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK3—melanoma	7.38e-06	2.06e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—melanoma	7.38e-06	2.06e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—melanoma	7.37e-06	2.06e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—melanoma	7.32e-06	2.05e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—melanoma	7.32e-06	2.05e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—melanoma	7.29e-06	2.04e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—melanoma	7.27e-06	2.03e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK3—melanoma	7.26e-06	2.03e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—melanoma	7.26e-06	2.03e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK1—melanoma	7.26e-06	2.03e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—melanoma	7.26e-06	2.03e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—melanoma	7.23e-06	2.02e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—melanoma	7.23e-06	2.02e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK1—melanoma	7.22e-06	2.02e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—melanoma	7.22e-06	2.02e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—melanoma	7.2e-06	2.01e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CTNNB1—melanoma	7.2e-06	2.01e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—melanoma	7.19e-06	2.01e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—melanoma	7.18e-06	2.01e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ALB—melanoma	7.17e-06	2e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—melanoma	7.1e-06	1.98e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—melanoma	7.09e-06	1.98e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—melanoma	7.08e-06	1.98e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—melanoma	7.07e-06	1.97e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—melanoma	7.06e-06	1.97e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—melanoma	7.03e-06	1.96e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK1—melanoma	7.02e-06	1.96e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—melanoma	7.02e-06	1.96e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—melanoma	7.02e-06	1.96e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—melanoma	7.01e-06	1.96e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—melanoma	6.99e-06	1.95e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—melanoma	6.99e-06	1.95e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—melanoma	6.99e-06	1.95e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NFKB1—melanoma	6.98e-06	1.95e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—melanoma	6.97e-06	1.95e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK1—melanoma	6.91e-06	1.93e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—melanoma	6.91e-06	1.93e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—melanoma	6.9e-06	1.93e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—melanoma	6.9e-06	1.93e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PRKCA—melanoma	6.89e-06	1.93e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—melanoma	6.88e-06	1.92e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—melanoma	6.88e-06	1.92e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—melanoma	6.86e-06	1.92e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—melanoma	6.85e-06	1.91e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ERCC2—melanoma	6.84e-06	1.91e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—melanoma	6.82e-06	1.91e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—melanoma	6.82e-06	1.91e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—melanoma	6.78e-06	1.89e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—melanoma	6.75e-06	1.89e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—melanoma	6.75e-06	1.89e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—melanoma	6.74e-06	1.88e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK3—melanoma	6.7e-06	1.87e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—melanoma	6.69e-06	1.87e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—melanoma	6.69e-06	1.87e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—melanoma	6.65e-06	1.86e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—melanoma	6.63e-06	1.85e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK3—melanoma	6.59e-06	1.84e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—melanoma	6.53e-06	1.82e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—melanoma	6.52e-06	1.82e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—melanoma	6.51e-06	1.82e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—melanoma	6.49e-06	1.81e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK3—melanoma	6.45e-06	1.8e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—melanoma	6.41e-06	1.79e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—melanoma	6.4e-06	1.79e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—melanoma	6.4e-06	1.79e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK1—melanoma	6.37e-06	1.78e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—melanoma	6.37e-06	1.78e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—melanoma	6.34e-06	1.77e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—melanoma	6.34e-06	1.77e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—melanoma	6.33e-06	1.77e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—melanoma	6.31e-06	1.76e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—melanoma	6.3e-06	1.76e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—melanoma	6.28e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—melanoma	6.28e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK1—melanoma	6.27e-06	1.75e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—melanoma	6.27e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—melanoma	6.27e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—melanoma	6.27e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—melanoma	6.26e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK1—melanoma	6.14e-06	1.72e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—melanoma	6.14e-06	1.71e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—melanoma	6.09e-06	1.7e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—melanoma	6.09e-06	1.7e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—melanoma	6.06e-06	1.69e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—melanoma	6.04e-06	1.69e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—melanoma	6.02e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—melanoma	6e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK3—melanoma	6e-06	1.67e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—melanoma	5.98e-06	1.67e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—melanoma	5.95e-06	1.66e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—melanoma	5.92e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—melanoma	5.92e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—melanoma	5.9e-06	1.65e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—melanoma	5.9e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—melanoma	5.9e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—melanoma	5.83e-06	1.63e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—melanoma	5.83e-06	1.63e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—melanoma	5.8e-06	1.62e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—melanoma	5.8e-06	1.62e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—melanoma	5.8e-06	1.62e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—melanoma	5.78e-06	1.61e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK1—melanoma	5.7e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—melanoma	5.7e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—melanoma	5.64e-06	1.58e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—melanoma	5.58e-06	1.56e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—melanoma	5.55e-06	1.55e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—melanoma	5.55e-06	1.55e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—melanoma	5.53e-06	1.54e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—melanoma	5.47e-06	1.53e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—melanoma	5.44e-06	1.52e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—melanoma	5.4e-06	1.51e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—melanoma	5.4e-06	1.51e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—melanoma	5.39e-06	1.51e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—melanoma	5.35e-06	1.49e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—melanoma	5.33e-06	1.49e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—melanoma	5.33e-06	1.49e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—melanoma	5.31e-06	1.48e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—melanoma	5.26e-06	1.47e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PPARG—melanoma	5.21e-06	1.46e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—melanoma	5.15e-06	1.44e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—melanoma	5.15e-06	1.44e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—melanoma	5.12e-06	1.43e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—melanoma	5.12e-06	1.43e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—melanoma	5.03e-06	1.41e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—melanoma	4.98e-06	1.39e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—melanoma	4.95e-06	1.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—melanoma	4.93e-06	1.38e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—melanoma	4.9e-06	1.37e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—melanoma	4.9e-06	1.37e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—melanoma	4.84e-06	1.35e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—melanoma	4.82e-06	1.35e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—melanoma	4.79e-06	1.34e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—melanoma	4.75e-06	1.33e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—melanoma	4.72e-06	1.32e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALB—melanoma	4.69e-06	1.31e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—melanoma	4.58e-06	1.28e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—melanoma	4.52e-06	1.26e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—melanoma	4.44e-06	1.24e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—melanoma	4.38e-06	1.22e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—melanoma	4.35e-06	1.22e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—melanoma	4.14e-06	1.16e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—melanoma	4.1e-06	1.15e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—melanoma	4.04e-06	1.13e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—melanoma	3.86e-06	1.08e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—melanoma	3.58e-06	9.99e-06	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—melanoma	3.15e-06	8.8e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—melanoma	2.52e-06	7.05e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—melanoma	2.06e-06	5.76e-06	CbGpPWpGaD
